Brief: Northstrive Biosciences plans meeting with FDA for its new obesity reducing therapy
10/03/2025 15:15
March 10 (Reuters) - PMGC Holdings Inc ELAB.O: NORTHSTRIVE BIOSCIENCES INC. SCHEDULES PRE-IND MEETING WITH FDA FOR EL-22, AN OBESITY THERAPY TARGETING FAT LOSS AND MUSCLE PRESERVATION IN COMBINATION WITH GLP-1 NORTHSTRIVE BIOSCIENCES : SCHEDULED A PRE-IND MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION FOR APRIL 23, 2025 Source text: nGNX7B0PkG Further company coverage: ELAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Holdings Signs Non-Binding Letter Of Intent To Acquire Majority Stake In US-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, And Semiconductor Markets
Brief: PMGC Holdings Offers $7.8 Million In Common Stock To Streeterville Capital
NASDAQ RESUMED AT 12:33 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:28 PM
NASDAQ RESUMED AT 09:46 AM